157 related articles for article (PubMed ID: 35428910)
21. CD160 receptor in CLL: Current state and future avenues.
Oumeslakht L; Aziz AI; Bensussan A; Ben Mkaddem S
Front Immunol; 2022; 13():1028013. PubMed ID: 36420268
[TBL] [Abstract][Full Text] [Related]
22. CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.
Peretz Y; He Z; Shi Y; Yassine-Diab B; Goulet JP; Bordi R; Filali-Mouhim A; Loubert JB; El-Far M; Dupuy FP; Boulassel MR; Tremblay C; Routy JP; Bernard N; Balderas R; Haddad EK; Sékaly RP
PLoS Pathog; 2012; 8(8):e1002840. PubMed ID: 22916009
[TBL] [Abstract][Full Text] [Related]
23. CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.
Viganò S; Banga R; Bellanger F; Pellaton C; Farina A; Comte D; Harari A; Perreau M
PLoS Pathog; 2014 Sep; 10(9):e1004380. PubMed ID: 25255144
[TBL] [Abstract][Full Text] [Related]
24. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
25. Identification of a novel CD160+ CD4+ T-lymphocyte subset in the skin: a possible role for CD160 in skin inflammation.
Abecassis S; Giustiniani J; Meyer N; Schiavon V; Ortonne N; Campillo JA; Bagot M; Bensussan A
J Invest Dermatol; 2007 May; 127(5):1161-6. PubMed ID: 17218942
[TBL] [Abstract][Full Text] [Related]
26. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
27. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
[TBL] [Abstract][Full Text] [Related]
28. [A Preliminary Study on the Expression of CD160 on NK Cells and Its Mechanism of Mediating NK Killing Effect].
Wang ZH; Liu HH; Ma N; Wang LH; Liu W; Tang B; Qiu ZX; Cen XN; Ren HY; Dong YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1559-1564. PubMed ID: 30295284
[TBL] [Abstract][Full Text] [Related]
29. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
30. Melanoma therapy: Check the checkpoints.
Furue M; Kadono T
J Dermatol; 2016 Feb; 43(2):121-4. PubMed ID: 26813076
[TBL] [Abstract][Full Text] [Related]
31. Increased CD160 expression on circulating natural killer cells in atherogenesis.
Zuo J; Shan Z; Zhou L; Yu J; Liu X; Gao Y
J Transl Med; 2015 Jun; 13():188. PubMed ID: 26071079
[TBL] [Abstract][Full Text] [Related]
32. [Expression of CD160 in natural killer (NK) cells from patients with active tuberculosis and its relationship with cell functions].
Yang B; Zhai F; An H; Cao Z; Liu Y; Wang R; Cheng X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Oct; 38(10):918-924. PubMed ID: 36163624
[TBL] [Abstract][Full Text] [Related]
33. Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on
Frazao A; Colombo M; Fourmentraux-Neves E; Messaoudene M; Rusakiewicz S; Zitvogel L; Vivier E; Vély F; Faure F; Dréno B; Benlalam H; Bouquet F; Savina A; Pasmant E; Toubert A; Avril MF; Caignard A
Cancer Immunol Res; 2017 Jul; 5(7):582-593. PubMed ID: 28576831
[TBL] [Abstract][Full Text] [Related]
34. Differential and tumor-specific expression of CD160 in B-cell malignancies.
Farren TW; Giustiniani J; Liu FT; Tsitsikas DA; Macey MG; Cavenagh JD; Oakervee HE; Taussig D; Newland AC; Calaminici M; Bensussan A; Jenner M; Gribben JG; Agrawal SG
Blood; 2011 Aug; 118(8):2174-83. PubMed ID: 21715317
[TBL] [Abstract][Full Text] [Related]
35. BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.
Merino J; Ramírez N; Moreno C; Toledo E; Fernández M; Sánchez-Ibarrola A
Clin Exp Immunol; 2007 Jul; 149(1):87-96. PubMed ID: 17425655
[TBL] [Abstract][Full Text] [Related]
36. Expression profiles of peripheral CD160+ lymphocytes during the course of healthy human pregnancy.
Barakonyi A; Weisdorn R; Miko E; Varga P; Bodis J; Szekeres-Bartho J; Szereday L
Am J Reprod Immunol; 2011 Aug; 66(2):137-42. PubMed ID: 21276121
[TBL] [Abstract][Full Text] [Related]
37. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
38. CD160 expression defines a uniquely exhausted subset of T lymphocytes in HTLV-1 infection.
Chibueze CE; Yoshimitsu M; Arima N
Biochem Biophys Res Commun; 2014 Oct; 453(3):379-84. PubMed ID: 25277889
[TBL] [Abstract][Full Text] [Related]
39. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
40. High Levels of CD244 Rather Than CD160 Associate With CD8
Wang X; Wang D; Du J; Wei Y; Song R; Wang B; Qiu S; Li B; Zhang L; Zeng Y; Zhao H; Kong Y
Front Immunol; 2022; 13():853522. PubMed ID: 35386693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
